Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sotalol

R Ruffy1

  • 1Division of Cardiology, University of Utah Medical Center, Salt Lake City 84132.

Journal of Cardiovascular Electrophysiology
|February 1, 1993
PubMed
Summary
This summary is machine-generated.

Sotalol, a dual-action antiarrhythmic drug, effectively suppresses most cardiac arrhythmias. Further trials are needed to compare its safety and efficacy against other treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of refractory congestive heart failure by cardiac resynchronization.

Minerva cardioangiologica·2003
Same author

Bedside presentations and patients' perceptions of their medical care.

The New England journal of medicine·1997
Same author

Chemical cardiac sympathetic denervation hampers defibrillation in the dog.

Journal of cardiovascular electrophysiology·1997
Same author

Radiofrequency delivery through a cooled catheter tip allows the creation of larger endomyocardial lesions in the ovine heart.

Journal of cardiovascular electrophysiology·1995
Same author

The automatic implantable defibrillator: it can be done, but should it?

Journal of cardiovascular electrophysiology·1995
Same author

Catheter ablation in a less privileged country: the importance of spreading the goods.

Pacing and clinical electrophysiology : PACE·1995
Same journal

Pulsed Field Ablation Is Associated With Fewer Post-Procedural Pericardial Inflammatory Symptoms Compared With Radiofrequency Ablation.

Journal of cardiovascular electrophysiology·2026
Same journal

Single-Cell Transcriptomics and Mendelian Randomization Analysis Reveal Key Genes in Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same journal

Relationship Between Nonuniform Isochrone-Area in Late Activation Mapping and Arrhythmogenic Substrates Related to Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same journal

Clinical Utility of Tissue Proximity Indication With a Variable-Loop Circular Catheter for Pulmonary Vein Isolation.

Journal of cardiovascular electrophysiology·2026
Same journal

Impact of Carina Width on Re-Ablation Rate of Atrial Fibrillation After Primary Cryoballoon-Ablation.

Journal of cardiovascular electrophysiology·2026
Same journal

Mediastinal Air Entrapment During Extravascular ICD Implantation: A Preventable Cause of Elevated Shock Impedance.

Journal of cardiovascular electrophysiology·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiology

Background:

  • Sotalol exhibits noncardioselective beta-adrenergic antagonism and Class III electrophysiologic action.
  • This dual profile provides significant antiarrhythmic properties.

Purpose of the Study:

  • To review the pharmacologic profile, efficacy, and safety of sotalol as an antiarrhythmic agent.
  • To highlight the need for further randomized controlled trials.

Main Methods:

  • Review of sotalol's pharmacokinetic properties (bioavailability, elimination half-life).
  • Analysis of its efficacy in suppressing various cardiac arrhythmias.
  • Examination of potential adverse effects and risk mitigation strategies.

Main Results:

  • Sotalol is highly bioavailable orally and eliminated unchanged in urine with a 15-17 hour half-life.

Related Experiment Videos

  • Effective in suppressing most arrhythmias, except those linked to prolonged ventricular repolarization.
  • Adverse effects include those of beta-blockade and QT prolongation.

    • Conclusions:

    • Sotalol possesses unique antiarrhythmic properties due to its dual mechanism.
    • Further research is essential to establish its comparative safety and efficacy in unselected patient populations.
    • Risk of torsade de pointes can be minimized by dose limitation and avoiding hypokalemia.